Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib-Reference-Cited by-同舟云学术

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib

Published:2016 Issue:4 Volume:1 Page:e000063
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Azuma Koichi,Hirashima Tomonori,Yamamoto Nobuyuki,Okamoto Isamu,Takahashi Toshiaki,Nishio Makoto,Hirata Taizo,Kubota Kaoru,Kasahara Kazuo,Hida Toyoaki,Yoshioka Hiroshige,Nakanishi Kaoru,Akinaga Shiro,Nishio Kazuto,Mitsudomi Tetsuya,Nakagawa Kazuhiko

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer;Mitsudomi;Cancer Sci,2007

3. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update;Masters;J Clin Oncol,2015

4. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci Transl Med,2011

5. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers;Yu;Clin Cancer Res,2013

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized treatment using predictive biomarkers in solid organ malignancies: A review;Tumori Journal;2024-08-02

2. AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells;Cancer Letters;2024-04

3. Non-canonical integrin signaling activates EGFR and RAS-MAPK-ERK signaling in small cell lung cancer;Theranostics;2023

4. Targeted therapies in advanced lung cancer—current landscapes and future projects;Treatment Landscape of Targeted Therapies in Oncology;2023

5. Extracellular vesicles induce aggressive lung cancer via non-canonical integrin-EGFR-KRAS signaling;2022-08-16